← board
PMN
distress 5/10 · elevated risk$13.99-3%today-50% from 52w high
Lead: Alzheimer's disease · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$64M
Runway
1.8 yrs
Shares 1y
-83%
Price & events
+51.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.5%
1D
-0.1%
1W
+31.0%
1M
+25.9%
3M
+51.2%
6M
-31.8%
1Y
-71.0%
2Y
-94.2%
5Y
-88.3%
All
Overview
- Market Cap
- $125.46M
- Volume
- 90.30K
- 52 Week Range
- $6.76 – $28.00
- Total Shares
- 8.97M
- Float Shares
- 4.60M
- Short %
- 2.29%
- % Held by Insiders
- 11.85%
- % Held by Institutions
- 74.37%
- RVOL
- 1.28x
- Beta
- -0.21
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- toward the end of 2026Guided 55%conferencedata presentationsecondaryPhase 1PMN310 · 12-month top-line data expected toward end of 2026SEC 8-K
- second quarter of 2026readoutPhase 1PMN310 · 6-month interim data from PRECISE-AD Phase 1b trialSEC 8-K
- September 10, 2025 at 12:30 p.m. Eastern Timeconferencedata presentationsecondaryPMN310 · Presentation at H.C. Wainwright 27th Annual Global Investment ConferenceSEC 8-K
- 2025-02-25trial initiationsecondaryPhase 1PMN310 · First patients dosed in Phase 1b PRECISE-AD trialSEC 8-K
- second half of 2024conferencedata presentationsecondaryPMN310 · present full dataset at upcoming medical meetingSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $32 (+131% upside) · 6 analysts
- 2026-07-08Roth CapitalBuy
- 2026-06-30Cantor FitzgeraldOverweight
- 2026-06-24HC Wainwright & Co.Buy
- 2026-06-08HC Wainwright & Co.Buy
- 2026-02-06GuggenheimBuy
- 2025-12-01HC Wainwright & Co.Buy
Competitors — Alzheimer's disease
- GSKGSK plc$217.0B · D1
- BMYBRISTOL MYERS SQUIBB CO$124.5B · D0
- AXSMAxsome Therapeutics, Inc.$12.3B · D0
- ACADACADIA PHARMACEUTICALS INC$4.2B · D0
- DNLIDenali Therapeutics Inc.$3.6B · D2
- NAMSNewAmsterdam Pharma Co N.V.$3.6B · D0
- MPLTMapLight Therapeutics, Inc.$1.5B · D2
- NMRANeumora Therapeutics, Inc.$281M · D5
- ANVSAnnovis Bio, Inc.$59M · D8
- INMBInmune Bio, Inc.$47M · D5
Recent news
- 2026-07-23Investor Update - ml-eu.globenewswire.com
- 2026-07-23Media & Investor Release - ml-eu.globenewswire.com
- 2026-07-23[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong - GlobeNewswire
- 2026-07-17PMN Q1 2026 Earnings: Better-Than-Expected Loss Drives Double-Digit Stock Gain - Annual Earnings Summary - dars.gov.et
- 2026-07-17$PMN stock is up 12% today. Here's what we see in our data. - Quiver Quantitative
- 2026-07-15 - GlobeNewswire
- 2026-07-15FDA grants priority review to Genentech’s Gazyva sBLA in pMN - The Pharma Letter
- 2026-07-15Guggenheim Sticks to Their Buy Rating for ProMIS Neurosciences (PMN) - The Globe and Mail
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.